What nonsense is everyone’s favorite reverse-merger pink sheet Coronacrapper, Cytodyn (CYDY), spewing in this holiday-shortened, and retail trader dominated week? Today, the 22nd of December, comes a press release with a clearly misleading headline.
Notice the use of the word “Approval“, which has a special meaning with regards to the FDA. INDs are never “approved”, they are either rejected or accepted. EINDs (Emergency INDs) are never approved, they are “authorized”. The use of “approval” in this context is misleading, as loserlimab has not been approved for anything by the FDA.
You can read more about EINDs on the FDA’s web site. What is important to note is that having an EIND accepted is neither noteworthy, nor newsworthy. It is a ho-hum, run-of-the-mill, everyday occurrence:
What is newsworthy, however, is the Form 4 filed last night by Cytodyn’s Klown Krew CFO Mike Mulholland, detailing the sale of millions of dollars worth of cheap stock. See the filing here.
Cytodyn is obviously hoping the press release, and curiously timed companion puff piece article by a tout (who happens to be affiliated with a paid promoter called “Streetwise Reports”), draws attention far far away from it.